475 related articles for article (PubMed ID: 23828140)
1. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.
Argüelles-Arias F; Castro-Laria L; Lobatón T; Aguas-Peris M; Rojas-Feria M; Barreiro-de Acosta M; Soto-Escribano P; Calvo-Moya M; Ginard-Vicens D; Chaparro-Sánchez M; Hernández-Durán M; Castro-Senosiain B; Fernández-Villaverde A; García-Sánchez V; Domínguez-Muñoz E; Caunedo-Álvarez A; Herrerías-Gutiérrez JM
Dig Dis Sci; 2013 Oct; 58(10):2949-54. PubMed ID: 23828140
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
4. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
5. Use of infliximab in pyoderma gangrenosum.
Hewitt D; Tait C
Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases.
Cocco A; Angelucci E; Viscido A; Caprilli R
Inflamm Bowel Dis; 2007 Oct; 13(10):1317-9. PubMed ID: 17508417
[No Abstract] [Full Text] [Related]
7. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
[TBL] [Abstract][Full Text] [Related]
8. Management of peristomal pyoderma gangrenosum.
Kiran RP; O'Brien-Ermlich B; Achkar JP; Fazio VW; Delaney CP
Dis Colon Rectum; 2005 Jul; 48(7):1397-403. PubMed ID: 15868233
[TBL] [Abstract][Full Text] [Related]
9. Concomitant occurrence of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease.
Goldberg I; Finkel O; Gat A; Sprecher E; de Morentin HM
Isr Med Assoc J; 2014 Mar; 16(3):168-70. PubMed ID: 24761705
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease.
Alkhouri N; Hupertz V; Mahajan L
Inflamm Bowel Dis; 2009 Jun; 15(6):803-6. PubMed ID: 18942748
[No Abstract] [Full Text] [Related]
11. Successful Use of Adalimumab for Treating Pyoderma Gangrenosum with Ulcerative Colitis under Corticosteroid-tapering Conditions.
Sagami S; Ueno Y; Tanaka S; Nagai K; Hayashi R; Chayama K
Intern Med; 2015; 54(17):2167-72. PubMed ID: 26328641
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Triple Combination Therapy for Recalcitrant Perineal Pyoderma Gangrenosum.
Shaath TS; Om A; Wolfe CM; Cohen GF
J Drugs Dermatol; 2019 Mar; 18(3):307-310. PubMed ID: 31020825
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
[TBL] [Abstract][Full Text] [Related]
14. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy.
Agarwal A; Andrews JM
Aliment Pharmacol Ther; 2013 Sep; 38(6):563-72. PubMed ID: 23914999
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review.
Sawka E; Zhou A; Latour E; Friedman M; Ortega-Loayza AG
Clin Rheumatol; 2021 Oct; 40(10):3963-3969. PubMed ID: 34002351
[TBL] [Abstract][Full Text] [Related]
16. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab.
López San Román A; Bermejo F; Aldanondo I; Carrera E; Boixeda D; Muñoz Zato E
Rev Esp Enferm Dig; 2004 Jun; 96(6):420-2; 422-4. PubMed ID: 15230672
[TBL] [Abstract][Full Text] [Related]
17. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients.
Vacas AS; Torre AC; Bollea-Garlatti ML; Warley F; Galimberti RL
Int J Dermatol; 2017 Apr; 56(4):386-391. PubMed ID: 28295267
[TBL] [Abstract][Full Text] [Related]
18. Infliximab for peristomal pyoderma gangrenosum.
Mimouni D; Anhalt GJ; Kouba DJ; Nousari HC
Br J Dermatol; 2003 Apr; 148(4):813-6. PubMed ID: 12752145
[TBL] [Abstract][Full Text] [Related]
19. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P
Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524
[TBL] [Abstract][Full Text] [Related]
20. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease.
Reguiaï Z; Grange F
Am J Clin Dermatol; 2007; 8(2):67-77. PubMed ID: 17428111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
